BioNTech (ADR) (BNTX)
Develops oncology medicines while commercializing the Pfizer-partnered Comirnaty vaccine.
Something off on this page? Send us feedback.
Markets Pfizer-partnered Comirnaty, its only commercial medicine, while developing oncology candidates across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies. Revenue remains tied to COVID-19 vaccine demand, and expansion beyond it depends on clinical results, regulatory approvals, collaborators and commercialization.
Markets Comirnaty, the Pfizer-partnered COVID-19 vaccine and its only approved commercial medicine, while developing cancer treatments across immunomodulators, antibody-drug conjugates and mRNA immunotherapies. Based in Mainz, the commercial business is anchored in a global collaboration, while oncology candidates remain investigational.
Capabilities span immunology, computational design and manufacturing, built from an oncology-focused research base and expanded through acquisitions. The same mRNA platform that supported Project Lightspeed now sits within a broader multi-platform development portfolio.
Revenue remains heavily dependent on declining COVID-19 vaccine demand. Expansion beyond that product depends on clinical outcomes, regulatory approvals, collaborator execution, manufacturing capacity and successful commercialization, while a founder-management transition and manufacturing consolidation are underway.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 16, 2026 | Berenberg Bank | Target | Target: $155 | Target: $140 |
| Sep 8, 2026 | BMO Capital | Downgrade | Target: $128 | Target: $105 |
| Aug 31, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $142 | Target: $136 |
| Aug 5, 2026 | Canaccord Genuity | Target | Target: $158 | Target: $142 |
| Jul 8, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $126 | Target: $119 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.15B · Total debt $362.0M · Total assets $23.29B · Shareholders' equity $20.33B
- Revenue
- $121.0M
- Operating income
- −$1.09B
- Net income
- −$940.3M
Reported in EUR, converted at the latest exchange rate
HistoryDividendAnnual yield
| Institutions | ≈ 18.60% | 46.73M ADS | |
|---|---|---|---|
| 318 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 56.90% | 142.95M ADS | |
| 8 holders · as of Sep 18, 2026 | |||
| Other | ≈ 24.50% | 61.53M ADS | |
| remainder | |||
251.20M ADS as of Aug 25, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Mar 2025 annual report; nothing newer is on file here.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Athos KgInsider | 40.49% | 101.70M | filed May 14, 2026 |
Ugur SahinInsider10 percent owner, officer: Chief Executive Officer | 15.81% | 39.71M ordinary | filed Sep 18, 2026 |
MIG Verwaltungs AGInstitution | 5.40% | 13.56M | filed Feb 14, 2020 |
FMR LLCInstitution | 3.01% | 7.57M ADS | as of Jun 30, 2026 |
Primecap Management Co/CA/Institution | 1.50% | 3.77M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 18, 2026 | Ugur Sahin | 10 percent owner, officer: Chief Executive Officer | −30,000 | $96.22 |
| Sep 17, 2026 | Ugur Sahin | 10 percent owner, officer: Chief Executive Officer | −34,000 | $98.60 |
| Sep 16, 2026 | Ugur Sahin | 10 percent owner, officer: Chief Executive Officer | −15,000 | $96.09 |
| Sep 15, 2026 | Ugur Sahin | 10 percent owner, officer: Chief Executive Officer | −34,000 | $96.49 |
| Sep 14, 2026 | Ugur Sahin | 10 percent owner, officer: Chief Executive Officer | −41,000 | $99.45 |
- Moderna
mRNA rival across seasonal COVID-19 vaccines and cancer immunotherapy
- Merck
Checkpoint and mRNA-oncology rival across solid tumors
- AstraZeneca (ADR)
Competes in HER2 ADCs and checkpoint therapy across solid tumors
- Summit Therapeutics
Direct PD-1×VEGF bispecific rival in lung and colorectal cancer
- Novavax
Protein-based alternative in seasonal COVID-19 vaccination
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioNTech (ADR) | $98.12 | +0.12% | $24.62B | — | — | 8.1 | −60.7% |
| Moderna | $171.67 | −0.74% | $68.62B | — | — | 30.8 | +2.1% |
| Merck | $148.13 | −0.92% | $369.24B | 119.6 | 17.2 | 5.6 | +5.1% |
| AstraZeneca (ADR) | $166.92 | −0.70% | $260.70B | 25.2 | 15.7 | 4.2 | +6.4% |
| Summit Therapeutics | $17.08 | +1.07% | $13.48B | — | — | — | — |
| Novavax | $10.29 | −1.19% | $1.71B | — | — | 4.1 | −76.3% |
| Median | 72.4 | 16.4 | 4.9 | +3.6% |